Investors are looking to tap the massive potential of China’s genomic industry, with a particular focus on companies that leverage large amounts of patient data to support drug development and testing services
CITIC Capital China has joined a consortium including China’s Humanwell Healthcare to acquire the sexual health division of Australia-listed medical products supplier Ansell for $600 million.
CANbridge Life Science, a Beijing-based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has raised a Series B round worth $25 million.
Blue Sky Alternative Investors will exit its stake in HPS, Australia’s largest provider of outsourced pharmacy services to hospitals, as healthcare business EBOS agreed to buy the asset for A$154 million ($116 million).
QIC, Goldman Sachs and Pagoda Investment – a China-focused private equity firm set up by a former QIC executive – have agreed to buy Icon Group, an Australian oncology services provider, from Quadrant Private Equity.
Chinese healthcare specialists Frontline BioVentures and WuXi Healthcare Ventures have merged, forming a new investment firm called 6 Dimensions Capital.
Yantai Zhenghai Bio-tech, a Chinese biotechnology company backed by CDH Investments, saw its stock gain 44.03% on its first day of trading following a RMB234 million ($34 million) IPO in Shenzhen.
The International Finance Corporation (IFC), the investment arm of the World Bank, is considering an investment of up to $75 million in Indian hospital chain Max Healthcare.
Highland Capital Management has raised approximately $147 million for an Asia and North America-focused healthcare fund, having received an anchor LP commitment from South Korea’s National Pension Service (NPS).
The International Finance Corporation (IFC), the investment arm of the World Bank, will exit its entire stake in Indian hospital chain Max Healthcare for INR4.2 billion ($65.6 million).
Hong Kong-listed private equity firm AID Partners has acquired Israel-based molecular diagnostics company GeneSort for $23 million.
By acquiring NextCode Health in 2015, WuXi Pharmatech combined its gene sequencing capabilities with one of the world's largest genome datasets. PE investors are backing the business to sell genomic testing services to Chinese patients
South Korean biopharmaceutical developer ExoCoBio has raised an $11 million Series A round from investors including SBI Investment, Atinum Investment, ID Ventures, and Dt&Investment.
China’s Ping An Insurance is launching a $1 billion fund that will make financial technology and healthcare investments globally as the company looks to establish a footprint beyond its home market.
Temasek Holdings and Chinese PE firm Yungfeng Capital have jointly led a $75 million Series B round for Wuxi NextCode, a genome sequencing analysis subsidiary of China-based contract research organization (CRO) WuXi PharmaTech.
The Singapore government and domestic GP Makara Capital have launched a S$1 billion ($716 million) private equity fund that will focus on intellectual property (IP)-driven companies.
KV Asia Capital has exited its 100% interest in Singaporean nursing home services provider Orange Valley Healthcare to a local media company for about S$164 million ($117.5 million).
Oriza Seed Venture Capital, an early-stage and growth-stage investment unit under China’s Oriza Holdings, has led a $25 million Series A round for EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical firm.
Korea’s government is playing a long game by propping up the local health tech start-up ecosystem. VCs that share this vision are identifying the obstacles and planning for growth
AGIC Capital has acquired 100% of Slovenia-based medical equipment supplier Fotona as part of a plan to expand operations in Asia with an emphasis on China. The deal will facilitate an exit for US private equity firm The Gores Group.
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million round of funding for CanSino Biologics, a China-based vaccine developer.
New Frontier, a private equity firm co-founded by Antony Leung (pictured), formerly Hong Kong's financial secretary, has invested in Best Unimed Medical Group, a Shenzhen-based third-party physicians group.
Lok Capital has led a $10 million Series A round of funding for Indian diabetes care provider Dr. Mohan’s Diabetes Specialities Centre.
A consortium led by True North Managers will buy a majority stake in India’s Religare Health Insurance (RHI) for INR10.4 billion ($162 million).